Results 121 to 130 of about 4,586,589 (282)

Sentiment analysis of social media responses to the approval of lecanemab for the treatment of Alzheimer's disease in Japan

Journal of Alzheimer's Disease Reports
Lecanemab, an anti-amyloid therapy for early Alzheimer's disease, received approval by the FDA and Japan in 2023. Public response on social media was scrutinized, aiming to obtain insights into communication and treatment development.
Kenichiro Sato, Yoshiki Niimi, Ryoko Ihara, Atsushi Iwata, Kiyotaka Nemoto, Tetsuaki Arai, Shinji Higashi, Ataru Igarashi, Kensaku Kasuga, Takeshi Iwatsubo   +9 more
doaj   +1 more source

Pharmacological and Clinical Heterogeneity of Anti-Amyloid Monoclonal Antibodies in Early Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Randomized Trials

Medical Sciences
Background: Anti-amyloid monoclonal antibodies represent the first disease-modifying therapeutic strategy targeting amyloid-β pathology in early Alzheimer’s disease (AD).
Albert Vamanu, Alexandra Mastaleru, Thomas Gabriel Schreiner, Gabriela Popescu, Adina Maria Roceanu, Andrei Ionut Cucu, Alexandru Patrascu, Georgiana-Anca Vulpoi, Robert-Valentin Bilcu, Romica Sebastian Cozma, Raluca Olariu, Cătălina Elena Bistriceanu, Roxana Covali, Dan Iulian Cuciureanu, Alin Ciubotaru   +14 more
doaj   +1 more source

Anti-amyloid therapies work for Alzheimer’s disease

Brain Communications, 2023
openaire   +3 more sources

Cerebral Small Vessel Disease in Immune‐Mediated Thrombotic Thrombocytopenic Purpura Patients During the Acute Phase and Disease Remission

American Journal of Hematology, EarlyView.
ABSTRACT Immune‐mediated thrombotic thrombocytopenic purpura (iTTP) is a life‐threatening thrombotic microangiopathy characterized by acute neurological manifestations and long‐term sequelae related to microvascular brain injury. Cerebral small vessel disease (cSVD), detectable on MRI through lacunes, microbleeds, white matter hyperintensities, and ...
Addolorata Truma, Francesco Maria Lo Russo, Giorgio Conte, Ilaria Mancini, Andrea Artoni, Juri Alessandro Giannotta, Barbara Ferrari, Pasquale Agosti, Maria Abbattista, Matteo Gagliardi, Eleonora Piccin, Marco Stroppi, Fabio Maria Triulzi, Flora Peyvandi   +13 more
wiley   +1 more source

Anti-Amyloid Monoclonal Antibodies in Early Alzheimer Disease: Lecanemab and Donanemab

Neurology International
Background/Objectives: Alzheimer disease (AD) causes progressive cognitive and functional loss and substantial caregiver and healthcare burden. Anti-amyloid monoclonal antibodies represent a shift toward biology-directed treatment in biomarker-confirmed ...
Ülkü Figen Demir, Fatmanur Karakuş Dilbaz   +1 more
doaj   +1 more source

Amyloid Biomarker Discordance in Patients Evaluated for Anti‐Amyloid Therapy [PDF]

Alzheimers Dement
AbstractBackgroundEvidence for abnormal amyloid‐β (Aβ) plaque accumulation is necessary prior to initiating anti‐amyloid therapy in early symptomatic Alzheimer’s disease (AD). While the clinical trials for lecanemab and related drugs utilized positron emission tomography (PET) to demonstrate brain amyloidosis, current appropriate use recommendations ...
Ramanan V, Graff‐Radford J, Bornhorst J, Johnson D, Cogswell P, Burkett B, Lowe V, Stricker N, Botha H, Jones D, McCarter S, Neth B, Jack C, Knopman D, Petersen R, Algeciras‐Schimnich A.   +15 more
europepmc   +2 more sources

Outcomes of Patients With AL Amyloidosis and End‐Stage Renal Disease After Initiation of Therapy

American Journal of Hematology, EarlyView.
ABSTRACT In AL amyloidosis, advanced renal disease can impact treatment options and cause significant morbidity. Patients with ESRD requiring dialysis are a group with currently unmet needs. In this collaborative study, we identified 362 patients from three European centers who initiated dialysis during the course of the disease.
Foteini Theodorakakou, Lilli Sophie Sester, Ute Hegenbart, Paolo Milani, Claudia Bellofiore, Erasmia Psimenou, Charikleia Gakiopoulou, Meletios A. Dimopoulos, Giovanni Palladini, Stefan O. Schönland, Efstathios Kastritis   +10 more
wiley   +1 more source

Investigating patient eligibility for anti-amyloid monoclonal antibody treatment of Alzheimer's disease: real-world data from an Austrian psychiatric memory clinic population

BJPsych Open
Background Pharmacological treatment options for patients with dementia owing to Alzheimer's disease are limited to symptomatic therapy. Recently, the US Food and Drug Administration approved the monoclonal antibody lecanemab for the treatment of amyloid-
Michaela Defrancesco, Elke R. Gizewski, Stephanie Mangesius, Malik Galijasevic, Irene Virgolini, Alexander Kroiss, Josef Marksteiner, Juliane Jehle, Burak Doganyigit, Alex Hofer   +9 more
doaj   +1 more source

Centrum Semiovale Perivascular Spaces Predict First Hemorrhagic Lesion in Asymptomatic Amyloid‐Positive Individuals

Annals of Neurology, EarlyView.
Objective Identification of cerebral amyloid angiopathy (CAA) before its hemorrhagic manifestations remains limited. We aimed to determine whether severe enlarged perivascular spaces in the centrum semiovale (EPVS‐CSO) identify a prehemorrhagic stage of sporadic CAA by predicting the first appearance of CAA‐related hemorrhagic lesions or incident ...
Baris Alten, Elif Gokcal, Reisa A. Sperling, Zahra Shirzadi, Jasmeer P. Chhatwal, M. Edip Gurol, Scott E. Kasner, Steven M. Greenberg, Brett L. Cucchiara   +8 more
wiley   +1 more source

Cerebrospinal Fluid Cytokine Expression and Relationships With Neurological Measures in Virologically Controlled People With HIV

Annals of Neurology, EarlyView.
Objective Quantify cytokines in cerebrospinal fluid (CSF) of virologically suppressed people with HIV (PWH) and people without HIV (PWoH) and correlate these with neuroimaging, neuropsychometric (NP), and neurodegenerative measurements. Methods CSF samples were collected from virologically suppressed PWH and demographically matched PWoH under a natural
Jack Peterson, Clarissa Xia, Govind Nair, Joseph Snow, Julia Stone, Gina Norato, Brandon Do, Samuel Darko, Kory Johnson, Swati Shah, Amanda Wiebold, Melina Jones, Avindra Nath, Darshan Pandya   +13 more
wiley   +1 more source